Traders Purchase Large Volume of The Medicines Put Options (MDCO)

The Medicines Company (NASDAQ:MDCO) was the recipient of unusually large options trading activity on Tuesday. Traders acquired 18,805 put options on the company. This is an increase of 1,831% compared to the typical daily volume of 974 put options.

In other news, CEO Mark Timney acquired 2,926 shares of The Medicines stock in a transaction dated Friday, December 21st. The shares were bought at an average cost of $17.90 per share, with a total value of $52,375.40. Following the purchase, the chief executive officer now owns 29,789 shares in the company, valued at approximately $533,223.10. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Christopher T. Cox acquired 50,300 shares of The Medicines stock in a transaction dated Friday, November 16th. The stock was purchased at an average cost of $19.73 per share, for a total transaction of $992,419.00. Following the completion of the purchase, the executive vice president now owns 60,308 shares in the company, valued at approximately $1,189,876.84. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,052,589 shares of company stock worth $20,865,236 over the last three months. Insiders own 10.29% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of MDCO. Northern Trust Corp boosted its stake in The Medicines by 1.7% during the second quarter. Northern Trust Corp now owns 906,505 shares of the company’s stock worth $33,269,000 after acquiring an additional 14,879 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in The Medicines by 114.6% during the third quarter. Nisa Investment Advisors LLC now owns 16,695 shares of the company’s stock worth $499,000 after acquiring an additional 8,915 shares in the last quarter. Seven Eight Capital LP bought a new position in The Medicines during the third quarter worth $607,000. Comerica Bank boosted its stake in The Medicines by 39.6% during the third quarter. Comerica Bank now owns 95,978 shares of the company’s stock worth $2,555,000 after acquiring an additional 27,209 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its stake in The Medicines by 23.5% during the third quarter. Candriam Luxembourg S.C.A. now owns 136,500 shares of the company’s stock worth $4,083,000 after acquiring an additional 26,000 shares in the last quarter.

A number of equities research analysts have recently commented on MDCO shares. Cowen set a $46.00 price objective on shares of The Medicines and gave the company a “buy” rating in a research note on Sunday, November 11th. Zacks Investment Research raised shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. BidaskClub raised shares of The Medicines from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 22nd. Oppenheimer set a $50.00 price objective on shares of The Medicines and gave the company a “buy” rating in a research note on Friday, November 9th. Finally, Wolfe Research started coverage on shares of The Medicines in a research note on Friday, December 14th. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $45.29.

Shares of NASDAQ MDCO opened at $23.74 on Thursday. The firm has a market cap of $1.80 billion, a P/E ratio of -2.83 and a beta of 1.18. The Medicines has a 12-month low of $16.69 and a 12-month high of $41.57. The company has a debt-to-equity ratio of 31.23, a quick ratio of 2.40 and a current ratio of 2.41.

COPYRIGHT VIOLATION NOTICE: This story was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.themarketsdaily.com/2019/02/14/traders-purchase-large-volume-of-the-medicines-put-options-mdco.html.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

Read More: What does earnings per share mean?

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply